Prostate cancer hormone drugs risky for some men

Aug 25, 2009 By CARLA K. JOHNSON , AP Medical Writer

(AP) -- A new study links hormone therapy for prostate cancer with a higher risk of death in older men who've had serious heart problems.

Hormone therapy suppresses the amount of testosterone produced, in turn causing prostate tumors to shrink or grow more slowly. The treatment, involving injections in a doctor's office, can help with more advanced disease when used with surgery or radiation.

But the side effects are troubling: impotence, , hot flashes, , fatigue and an increased risk for diabetes and heart disease.

For the new study, appearing in Wednesday's , researchers followed more than 5,000 men with prostate cancer that hadn't spread. The men, most in their 60s and 70s, were followed for an average of five years.

All the patients had brachytherapy, a type of radiation treatment, at one Illinois treatment center. Thirty percent of them also took hormone therapy for an average of four months.

Five percent of the men in the study had a history of heart failure or heart attack and 43 of those men died. Among those with , the hormone treatment was linked with a 96 percent higher risk of death after adjusting for other risk factors.

In raw numbers, of the 95 men on hormone therapy who also had a history of serious heart problems, 25 died; and of the 161 men not on hormone therapy who also had a history of heart problems, 18 died.

"Our results should heighten awareness about the potential for harm with hormonal therapy for men with pre-existing heart disease," said lead author Dr. Akash Nanda of the Harvard Radiation Oncology Program in Boston.

The study was observational, meaning the men chose their treatment with their doctors, rather than being randomly assigned to get one treatment or another. That's a less rigorous approach and means the deaths could have been caused by factors other than the hormone therapy. The small number of deaths also calls for additional research.

But the findings line up with prior studies that have found that sicker men don't benefit from hormone therapy when it's added to radiation. And hormone therapy used alone in older men has been linked to a slightly heightened risk of death.

"For those who've been following the field, this is not surprising at all," said Dr. Stephen Freedland, a Duke University specialist, who wasn't involved in the study.

Freedland said that although some patients benefit from , it's dangerous in the wrong patients. The drugs can increase insulin resistance and raise cholesterol. They increase fat, too.

He likened it to the opposite of performance-enhancing drugs some athletes have taken: "You take away the muscles and give him fat."

In some men, the hormone-blocking treatment, sometimes called chemical castration, is given as a first step before brachytherapy to reduce the size of the prostate. In the study, the drugs given were leuprolide or goserelin injections combined with oral bicalutamide or flutamide.

The treatment costs about $1,400 a month.

The study was funded by Brigham and Women's Hospital and the Dana-Farber Cancer Institute in Boston.

---

On the Net:

JAMA: http://jama.ama-assn.org

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Phase 3 study may be game-changer for acute myeloid leukemia

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

9 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

15 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

15 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.